Surrey Heartlands

Joint Formulary & PAD

Dimethyl fumarate - Psoriasis

You are here : Home > Formulary Search > Dimethyl fumarate - Psoriasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :

Documentation

Guidelines (Local)
Psoriasis - High cost immunomodulator treatment pathway - October 23.pdf
NICE Technology Appraisal
NICE TA475 - Dimethyl fumarate (Skilarence) for Psoriasis
Evidence Review
Dimethyl fumarate (Skilarence) for Psoriasis - Briefing paper - Dec-17

PAD Profile

ChemicalSubstance :
Dimethyl fumarate
Indication :
Psoriasis
Group Name :
Keywords :
Biologic, NICE, immunosuppressant, fumaric acid ester, DMARD, bDmard, Disease modulating, Dermatology, biosimilar
Brand Names Include :
Skilarence
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Dimethyl fumarate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriasis.

Committee Recommendations (3)

04 Oct 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

18 Dec 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Dimethyl Fumarate (Skilarence) as a treatment option for the treatment of moderate to severe Plaque Psoriasis in line with NICE TA475.

Prescribing will be by hospital specialists only, in line with NICE TA475 using Blueteq initiation and continuation forms. Dimethyl Fumarate (Skilarence) will be considered RED on the traffic light system.